<VariationArchive VariationID="987921" VariationName="NM_000516.5:c.(?_-424)_(257_?)dup" VariationType="Duplication" Accession="VCV000987921" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-15" DateCreated="2020-12-07" MostRecentSubmission="2020-12-07">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="975888" VariationID="987921">
      <GeneList>
        <Gene Symbol="GNAS" FullName="GNAS complex locus" GeneID="2778" HGNC_ID="HGNC:4392" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>20q13.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58839748" stop="58911192" display_start="58839748" display_stop="58911192" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57414794" stop="57486249" display_start="57414794" display_stop="57486249" Strand="+" />
          </Location>
          <OMIM>139320</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000516.5:c.(?_-424)_(257_?)dup</Name>
      <VariantType>Duplication</VariantType>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000516.5:c.(?_-424)_(257_?)dup AND multiple conditions" Accession="RCV001269333" Version="3">
        <ClassifiedConditionList TraitSetID="46922">
          <ClassifiedCondition DB="MedGen" ID="C0010481">Cushing syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0242292">McCune-Albright syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4540135">Pituitary adenoma 3, multiple types</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0334041">Progressive osseous heteroplasia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0033806">Pseudohypoparathyroidism</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1864100">Pseudohypoparathyroidism type 1B</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C2932716">Pseudohypoparathyroidism type 1C</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0033835">Pseudopseudohypoparathyroidism</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-10-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-10-04" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-12-07" MostRecentSubmission="2020-12-07">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="46922" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5691" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ECTOPIC OSSIFICATION, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Osseus Heteroplasia, Progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive osseous heteroplasia</ElementValue>
                <XRef ID="Progressive+osseous+heteroplasia/5985" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008153" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">POH</ElementValue>
                <XRef Type="MIM" ID="166350" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="109" />
                <XRef ID="109" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="2762" DB="Orphanet" />
              <XRef ID="C0334041" DB="MedGen" />
              <XRef ID="MONDO:0008153" DB="MONDO" />
              <XRef Type="MIM" ID="166350" DB="OMIM" />
              <XRef Type="primary" ID="HP:0025027" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="2828" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">McCune-Albright syndrome</ElementValue>
                <XRef ID="McCune+Albright+syndrome/4524" DB="Genetic Alliance" />
                <XRef ID="MONDO:0018919" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright's disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright's Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">McCune-Albright syndrome, somatic, mosaic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albright syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MAS</ElementValue>
                <XRef Type="MIM" ID="174800" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PFD</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">POFD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6995" />
                <XRef ID="6995" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fibrous dysplasia / McCune-Albright syndrome (FD/MAS), the result of an early embryonic postzygotic somatic activating pathogenic variant in GNAS (encoding the cAMP pathway-associated G-protein, Gsα), is characterized by involvement of the skin, skeleton, and certain endocrine organs. However, because Gsα signaling is ubiquitous, additional tissues may be affected. Café au lait skin macules are common and are usually the first manifestation of the disease, apparent at or shortly after birth. Fibrous dysplasia (FD), which can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton, can range from an isolated, asymptomatic monostotic lesion discovered incidentally to severe disabling polyostotic disease involving practically the entire skeleton and leading to progressive scoliosis, facial deformity, and loss of mobility, vision, and/or hearing. Endocrinopathies include: Gonadotropin-independent precocious puberty resulting from recurrent ovarian cysts in girls and autonomous testosterone production in boys; Testicular lesions with or without associated gonadotropin-independent precocious puberty; Thyroid lesions with or without non-autoimmune hyperthyroidism; Growth hormone excess; FGF23-mediated phosphate wasting with or without hypophosphatemia in association with fibrous dysplasia; and Neonatal hypercortisolism. The prognosis for individuals with FD/MAS is based on disease location and severity.</Attribute>
                <XRef ID="NBK274564" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">25719192</ID>
                <ID Source="BookShelf">NBK274564</ID>
              </Citation>
              <Citation Type="review" Abbrev="Medical Genetics Summaries">
                <ID Source="BookShelf">NBK66130</ID>
              </Citation>
              <XRef ID="562" DB="Orphanet" />
              <XRef ID="C0242292" DB="MedGen" />
              <XRef ID="MONDO:0018919" DB="MONDO" />
              <XRef Type="MIM" ID="174800" DB="OMIM" />
            </Trait>
            <Trait ID="4057" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pseudohypoparathyroidism Type IB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IB</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1B</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1B/6036" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011301" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1B</ElementValue>
                <XRef Type="MIM" ID="603233" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10680" />
                <XRef ID="10680" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="94089" DB="Orphanet" />
              <XRef ID="C1864100" DB="MedGen" />
              <XRef ID="MONDO:0011301" DB="MONDO" />
              <XRef Type="MIM" ID="603233" DB="OMIM" />
            </Trait>
            <Trait ID="4060" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Albright hereditary osteodystrophy without multiple hormone resistance</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudopseudohypoparathyroidism</ElementValue>
                <XRef ID="Pseudopseudohypoparathyroidism/6049" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012912" DB="MONDO" />
                <XRef ID="237659007" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPHP</ElementValue>
                <XRef Type="MIM" ID="612463" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7860" />
                <XRef ID="7860" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79445" DB="Orphanet" />
              <XRef ID="C0033835" DB="MedGen" />
              <XRef ID="MONDO:0012912" DB="MONDO" />
              <XRef Type="MIM" ID="612463" DB="OMIM" />
            </Trait>
            <Trait ID="177" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cushing's syndrome</ElementValue>
                <XRef ID="Cushing%27s+Syndrome/2039" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Cushing syndrome</ElementValue>
                <XRef ID="HP:0003118" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0018912" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nodular primary adrenocortical dysplasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adrenal hyperfunction resulting from pituitary acth excess</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ectopic adrenocorticotropic hormone syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperadrenocorticism</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6224" />
                <XRef ID="6224" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="189427" DB="Orphanet" />
              <XRef ID="C0010481" DB="MedGen" />
              <XRef ID="MONDO:0018912" DB="MONDO" />
            </Trait>
            <Trait ID="38135" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pituitary adenoma 3, multiple types</ElementValue>
                <XRef ID="MONDO:0054665" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PITUITARY ADENOMA 3, GROWTH HORMONE-SECRETING, SOMATIC</ElementValue>
                <XRef Type="Allelic variant" ID="139320.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0008" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PITUITARY ADENOMA 3, ACTH-SECRETING, SOMATIC</ElementValue>
                <XRef Type="Allelic variant" ID="139320.0012" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PITA3</ElementValue>
                <XRef Type="MIM" ID="617686" DB="OMIM" />
              </Symbol>
              <XRef ID="C4540135" DB="MedGen" />
              <XRef ID="MONDO:0054665" DB="MONDO" />
              <XRef Type="MIM" ID="617686" DB="OMIM" />
            </Trait>
            <Trait ID="3403" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism</ElementValue>
                <XRef ID="HP:0000852" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0019992" DB="MONDO" />
                <XRef ID="58976002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10758" />
                <XRef ID="10758" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="97593" DB="Orphanet" />
              <XRef ID="C0033806" DB="MedGen" />
              <XRef ID="MONDO:0019992" DB="MONDO" />
              <XRef Type="primary" ID="HP:0000852" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="3404" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PSEUDOHYPOPARATHYROIDISM, TYPE IC</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0039" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0040" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0036" DB="OMIM" />
                <XRef Type="Allelic variant" ID="139320.0038" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHP IC</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism type 1C</ElementValue>
                <XRef ID="Pseudohypoparathyroidism+type+1C/6037" DB="Genetic Alliance" />
                <XRef ID="MONDO:0012911" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1C</ElementValue>
                <XRef Type="MIM" ID="612462" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10681" />
                <XRef ID="10681" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79444" DB="Orphanet" />
              <XRef ID="C2932716" DB="MedGen" />
              <XRef ID="MONDO:0012911" DB="MONDO" />
              <XRef Type="MIM" ID="612462" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2860438" SubmissionDate="2020-11-16" DateLastUpdated="2020-12-07" DateCreated="2020-12-07">
        <ClinVarSubmissionID localKey="NM_000516.5:c.(?_-424)_(257_?)dup|OMIM:219080;174800;166350;617686;103580;603233;612462;612463" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001448278" DateUpdated="2020-12-07" DateCreated="2020-12-07" Type="SCV" Version="1" SubmitterName="Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital" OrgID="507199" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-10-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000516.5:c.(?_-424)_(257_?)dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="219080" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="174800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="166350" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617686" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="103580" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603233" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612462" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612463" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8555056</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2860438" TraitType="Disease" MappingType="XRef" MappingValue="103580" MappingRef="OMIM">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2860438" TraitType="Disease" MappingType="XRef" MappingValue="174800" MappingRef="OMIM">
        <MedGen CUI="C0242292" Name="McCune-Albright syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2860438" TraitType="Disease" MappingType="XRef" MappingValue="617686" MappingRef="OMIM">
        <MedGen CUI="C4540135" Name="Pituitary adenoma 3, multiple types" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2860438" TraitType="Disease" MappingType="XRef" MappingValue="612463" MappingRef="OMIM">
        <MedGen CUI="C0033835" Name="Pseudopseudohypoparathyroidism" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2860438" TraitType="Disease" MappingType="XRef" MappingValue="166350" MappingRef="OMIM">
        <MedGen CUI="C0334041" Name="Progressive osseous heteroplasia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2860438" TraitType="Disease" MappingType="XRef" MappingValue="612462" MappingRef="OMIM">
        <MedGen CUI="C2932716" Name="Pseudohypoparathyroidism type 1C" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2860438" TraitType="Disease" MappingType="XRef" MappingValue="219080" MappingRef="OMIM">
        <MedGen CUI="C1857451" Name="ACTH-independent macronodular adrenal hyperplasia 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2860438" TraitType="Disease" MappingType="XRef" MappingValue="603233" MappingRef="OMIM">
        <MedGen CUI="C1864100" Name="Pseudohypoparathyroidism type 1B" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

